DrugPatentWatch Database Preview
Alnylam Pharms Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for ALNYLAM PHARMS INC, and when can generic versions of ALNYLAM PHARMS INC drugs launch?
ALNYLAM PHARMS INC has two approved drugs.
There are thirty-three US patents protecting ALNYLAM PHARMS INC drugs.
There are six hundred and thirty-seven patent family members on ALNYLAM PHARMS INC drugs in forty-six countries and fourteen supplementary protection certificates in eleven countries.
Summary for Alnylam Pharms Inc
| International Patents: | 637 |
| US Patents: | 33 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Alnylam Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | 9,133,461 | Start Trial | Y | Y | Start Trial | ||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,822,668 | Start Trial | Y | Start Trial | |||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 9,567,582 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Alnylam Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 090641 | Start Trial |
| Japan | 2019147846 | Start Trial |
| Denmark | 2836595 | Start Trial |
| Canada | 2685127 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alnylam Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2937418 | 2019C/501 | Belgium | Start Trial | PRODUCT NAME: PATISIRAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1320 20180829 |
| 2937418 | C201930007 | Spain | Start Trial | PRODUCT NAME: PATISIRAN; NATIONAL AUTHORISATION NUMBER: EU/1/18/1320; DATE OF AUTHORISATION: 20180827; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1320; DATE OF FIRST AUTHORISATION IN EEA: 20180827 |
| 2937418 | 300965 | Netherlands | Start Trial | PRODUCT NAME: -; REGISTRATION NO/DATE: EU/1/18/1320 20180829 |
| 1407044 | 132019000000031 | Italy | Start Trial | PRODUCT NAME: PATISIRAN(ONPATTRO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1320, 20180829 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
